JP3782818B2 - インスリン抵抗性の処置のためのオルト置換安息香酸誘導体 - Google Patents

インスリン抵抗性の処置のためのオルト置換安息香酸誘導体 Download PDF

Info

Publication number
JP3782818B2
JP3782818B2 JP2004515007A JP2004515007A JP3782818B2 JP 3782818 B2 JP3782818 B2 JP 3782818B2 JP 2004515007 A JP2004515007 A JP 2004515007A JP 2004515007 A JP2004515007 A JP 2004515007A JP 3782818 B2 JP3782818 B2 JP 3782818B2
Authority
JP
Japan
Prior art keywords
methyl
amino
benzoic acid
phenoxy
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2004515007A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005529970A5 (https=
JP2005529970A (ja
Inventor
リー，ランナ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0201935A external-priority patent/SE0201935D0/xx
Priority claimed from SE0203826A external-priority patent/SE0203826D0/xx
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2005529970A publication Critical patent/JP2005529970A/ja
Publication of JP2005529970A5 publication Critical patent/JP2005529970A5/ja
Application granted granted Critical
Publication of JP3782818B2 publication Critical patent/JP3782818B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2004515007A 2002-06-20 2003-06-17 インスリン抵抗性の処置のためのオルト置換安息香酸誘導体 Expired - Lifetime JP3782818B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0201935A SE0201935D0 (sv) 2002-06-20 2002-06-20 Therapeutic agents
SE0203826A SE0203826D0 (sv) 2002-12-20 2002-12-20 Therapeutic agents
PCT/GB2003/002584 WO2004000790A1 (en) 2002-06-20 2003-06-17 Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2006019068A Division JP2006182782A (ja) 2002-06-20 2006-01-27 インスリン抵抗性の処置のためのオルト置換安息香酸誘導体

Publications (3)

Publication Number Publication Date
JP2005529970A JP2005529970A (ja) 2005-10-06
JP2005529970A5 JP2005529970A5 (https=) 2006-01-05
JP3782818B2 true JP3782818B2 (ja) 2006-06-07

Family

ID=30002442

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004515007A Expired - Lifetime JP3782818B2 (ja) 2002-06-20 2003-06-17 インスリン抵抗性の処置のためのオルト置換安息香酸誘導体
JP2006019068A Pending JP2006182782A (ja) 2002-06-20 2006-01-27 インスリン抵抗性の処置のためのオルト置換安息香酸誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2006019068A Pending JP2006182782A (ja) 2002-06-20 2006-01-27 インスリン抵抗性の処置のためのオルト置換安息香酸誘導体

Country Status (22)

Country Link
US (1) US7355069B2 (https=)
EP (1) EP1517883B8 (https=)
JP (2) JP3782818B2 (https=)
KR (1) KR20050014013A (https=)
CN (1) CN1319938C (https=)
AR (1) AR039713A1 (https=)
AT (1) ATE386013T1 (https=)
AU (1) AU2003240099B2 (https=)
BR (1) BR0311932A (https=)
CA (1) CA2489834C (https=)
DE (1) DE60319084T2 (https=)
DK (1) DK1517883T3 (https=)
ES (1) ES2299702T3 (https=)
IL (1) IL165671A0 (https=)
IS (1) IS7627A (https=)
MX (1) MXPA04012686A (https=)
NO (1) NO20045353L (https=)
PL (1) PL375074A1 (https=)
PT (1) PT1517883E (https=)
RU (1) RU2004137094A (https=)
TW (1) TWI282784B (https=)
WO (1) WO2004000790A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262118B1 (en) * 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
US7576131B2 (en) * 1999-06-04 2009-08-18 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
SE0104333D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
FR2875805B1 (fr) * 2004-09-27 2006-12-29 Genfit S A Composes derives de n-(benzyl) phenylacetamide substitues, preparation et utilisations
GB0522433D0 (en) * 2005-11-03 2005-12-14 Astrazeneca Ab Therapeutic agents
GB0522431D0 (en) * 2005-11-03 2005-12-14 Astrazeneca Ab Chemical process

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK148576A (da) 1975-04-18 1976-10-19 Boehringer Mannheim Gmbh Fenylalkankarbonsyrederivater og fremgangsmade til deres fremstilling
DE19615263A1 (de) 1996-04-18 1997-10-23 Bayer Ag Benzyloxy-substituierte Phenylglycinolamide
BR9814087A (pt) 1997-10-17 2000-10-03 Aventis Pharm Prod Inc Processos para mediar a atividade do receptor de ppar-gama, e para tratar uma condição fisiológica em um paciente
EP1040108B1 (en) 1997-12-19 2004-02-25 Schering Aktiengesellschaft Ortho-anthranilamide derivatives as anti-coagulants
SE9801992D0 (sv) 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
GB9822473D0 (en) 1998-10-16 1998-12-09 Glaxo Group Ltd Chemical compounds
NZ515086A (en) 1999-04-28 2003-10-31 Aventis Pharma Gmbh Di-aryl acid derivatives as PPAR receptor ligands
EP1177176B1 (en) 1999-04-28 2006-04-19 Aventis Pharma Deutschland GmbH Tri-aryl acid derivatives as ppar receptor ligands
JP4618845B2 (ja) 1999-06-09 2011-01-26 杏林製薬株式会社 ヒトペルオキシゾーム増殖薬活性化受容体（ＰＰＡＲ）αアゴニストとしての置換フェニルプロピオン酸誘導体
GB9919411D0 (en) 1999-08-18 1999-10-20 Zeneca Ltd Chemical compounds
SE0000772D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab Chemical compounds
US6509374B2 (en) 2000-04-17 2003-01-21 Novo Nordisk A/S Compounds, their preparation and use
SE0003766D0 (sv) 2000-10-18 2000-10-18 Astrazeneca Ab Novel formulation
EG26979A (en) 2000-12-21 2015-03-01 Astrazeneca Ab Chemical compounds
GB0116955D0 (en) 2001-07-11 2001-09-05 Syngenta Ltd Weed control process
GB0121337D0 (en) 2001-09-04 2001-10-24 Astrazeneca Ab Chemical compounds
GB0121621D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
GB0121622D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
TWI331143B (en) 2001-09-08 2010-10-01 Astrazeneca Uk Ltd Benzothiadiazepine derivatives, process for preparing them, and pharmaceutical composition comprising them
SE0104333D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
GB0229931D0 (en) 2002-12-21 2003-01-29 Astrazeneca Ab Therapeutic agents
SE0104334D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
GB0209467D0 (en) 2002-04-25 2002-06-05 Astrazeneca Ab Chemical compounds
GB0213669D0 (en) 2002-06-14 2002-07-24 Astrazeneca Ab Chemical compounds
US7351858B2 (en) 2002-06-20 2008-04-01 Astrazeneca Ab Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance
SE0201936D0 (sv) 2002-06-20 2002-06-20 Astrazeneca Ab Therapeutic agents
SE0201937D0 (sv) 2002-06-20 2002-06-20 Astrazeneca Ab Therapeutic agents
GB0314130D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314136D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314131D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314129D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314075D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314078D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314260D0 (en) 2003-06-19 2003-07-23 Astrazeneca Ab Therapeutic agents

Also Published As

Publication number Publication date
US20050256198A1 (en) 2005-11-17
AU2003240099A1 (en) 2004-01-06
RU2004137094A (ru) 2005-08-10
ATE386013T1 (de) 2008-03-15
TWI282784B (en) 2007-06-21
IS7627A (is) 2005-01-05
DK1517883T3 (da) 2008-05-26
MXPA04012686A (es) 2005-03-23
DE60319084D1 (de) 2008-03-27
CA2489834C (en) 2006-10-03
CA2489834A1 (en) 2003-12-31
DE60319084T2 (de) 2009-01-29
PL375074A1 (en) 2005-11-14
TW200409747A (en) 2004-06-16
US7355069B2 (en) 2008-04-08
HK1073838A1 (en) 2005-10-21
EP1517883A1 (en) 2005-03-30
CN1675171A (zh) 2005-09-28
ES2299702T3 (es) 2008-06-01
AR039713A1 (es) 2005-03-09
AU2003240099B2 (en) 2007-02-01
EP1517883B1 (en) 2008-02-13
PT1517883E (pt) 2008-04-21
IL165671A0 (en) 2006-01-15
BR0311932A (pt) 2005-03-22
JP2006182782A (ja) 2006-07-13
NO20045353L (no) 2005-01-20
KR20050014013A (ko) 2005-02-05
JP2005529970A (ja) 2005-10-06
EP1517883B8 (en) 2008-05-21
WO2004000790A1 (en) 2003-12-31
CN1319938C (zh) 2007-06-06

Similar Documents

Publication Publication Date Title
US7521461B2 (en) Benzoic acid derivatives as modulators of PPAR alpha and gamma
CA2469302A1 (en) Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar)
JP3782818B2 (ja) インスリン抵抗性の処置のためのオルト置換安息香酸誘導体
JP3810770B2 (ja) ＰＰＡＲαの選択的アンタゴニストとしての３−フェニル−２−アリールアルキルチオプロピオン酸誘導体
AU2003240100B2 (en) Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance
US7351858B2 (en) Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance
HK1073838B (en) Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance
UA78050C2 (en) Ortho-benzoic acid derivatives for treating insulin resistance
HK1074779B (en) Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance
HK1068604B (en) Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050906

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050906

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20050906

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20050906

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20051021

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20051027

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060127

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20060228

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20060310

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100317

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100317

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110317

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130317

Year of fee payment: 7